Sacituzumab govitecan-hziy

Drug Overview:

Sacituzumab govitecan-hziy is an antibody-drug conjugate (ADC) used for the treatment of specific advanced or metastatic cancers. It is designed to deliver a potent chemotherapy agent directly to tumor cells that express the Trop-2 protein, minimizing damage to healthy tissues.

• Generic Name: Sacituzumab govitecan-hziy
• US Brand Name: Trodelvy®
• Drug Class: Antibody-Drug Conjugate (ADC) / Trop-2-directed antibody and topoisomerase I inhibitor conjugate
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Approved for:

1. Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) in adults who have received two or more prior systemic therapies, at least one for metastatic disease.
2. Locally advanced or metastatic urothelial cancer (mUC) in adults who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
3. Hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer in adults with metastatic disease or who have developed recurrence during or within 12 months of completing adjuvant chemotherapy, and have received endocrine-based therapy and at least two additional systemic therapies for metastatic disease.

What Is It and How Does It Work? (Mechanism of Action):

Sacituzumab govitecan is a targeted therapy known as an antibody-drug conjugate (ADC), designed for precise tumor cell killing.

• Molecular Target: The antibody component targets Trop-2, a cell surface protein overexpressed in many epithelial cancers.
• Cellular Impact: After binding to Trop-2, the drug is internalized into the cancer cell. Inside, the active cytotoxic payload, SN-38 (a topoisomerase I inhibitor), is released.
• Result: SN-38 binds to and stabilizes the topoisomerase I-DNA complex, preventing DNA repair. This causes irreparable DNA damage, leading to cancer cell apoptosis (programmed cell death).
• Targeted Therapy Characteristic: As an ADC, it is a “smart drug” that delivers chemotherapy directly to tumor cells, maximizing anti-cancer effect while minimizing damage to healthy tissues.

FDA Approved Clinical Indications:

Oncological Uses:

• Triple-Negative Breast Cancer (TNBC): Treatment of unresectable locally advanced or metastatic TNBC in adults who have received two or more prior systemic therapies.
• Hormone Receptor-Positive, HER2-Negative Breast Cancer: Treatment of metastatic disease in adults who have received endocrine-based therapy and at least two additional systemic therapies.
• Urothelial Cancer: Treatment of locally advanced or metastatic urothelial cancer in adults who have previously received a platinum-containing chemotherapy and a PD-1/PD-L1 inhibitor.

Non-Oncological Uses:

There are currently no FDA-approved non-oncological indications.

Dosage and Administration Protocols:

Sacituzumab Govitecan-hziy is administered as an intravenous infusion over multiple cycles, requiring rigorous premedication due to the risk of infusion reactions and managing its potent hematologic toxicity.

Renal and Hepatic Dose Adjustments

• Renal Impairment: No specific initial dose adjustment is required for patients with mild to moderate renal impairment. Data is limited in severe renal impairment.
• Hepatic Impairment: Dose adjustments are generally not required for mild hepatic impairment. Use in patients with moderate or severe hepatic impairment has not been established and requires caution due to the drug’s high potential for toxicity.
• Toxicity Adjustments: Dose reduction to 7.5 mg/kg is mandatory for managing dose-limiting toxicities, particularly severe neutropenia, which is common.

Clinical Efficacy and Research Results:

The approval of sacituzumab govitecan is based on robust phase III trials (ASCENT for TNBC, TROPiCS-02 for HR+/HER2- breast cancer, TROPHY-U-01 for UC), with data continuously maturing (2020-2025).

• Overall Survival in TNBC (ASCENT): In patients with pretreated mTNBC, sacituzumab govitecan improved median overall survival to 11.8 months compared to 6.9 months with physician’s choice chemotherapy. It also significantly improved progression-free survival (PFS).
• Overall Survival in HR+/HER2- Breast Cancer (TROPiCS-02): Improved median overall survival to 14.4 months vs. 11.2 months with chemotherapy in heavily pretreated patients.
• Objective Response Rate in Urothelial Cancer: In the TROPHY-U-01 cohort, the confirmed objective response rate (ORR) was 27.4% in platinum- and checkpoint inhibitor-refractory patients, with a median duration of response of 7.2 months.
• Contemporary Context: It is now a standard later-line therapy in these settings. Ongoing research is evaluating its efficacy in earlier lines of treatment and in other Trop-2 expressing cancers (e.g., lung, endometrial).

Safety Profile and Side Effects:

Black Box Warning:

• Severe Neutropenia: Can cause severe or life-threatening neutropenia.
• Severe Diarrhea: Can cause severe diarrhea.

Common Side Effects (>20%):

• Hematologic: Severe neutropenia, anemia, and leukopenia.
• Gastrointestinal: Severe diarrhea, nausea, vomiting, constipation, decreased appetite.
• Constitutional: Fatigue, alopecia.
• Dermatological: Rash.
• Other: Abdominal pain.

Management Strategies:

• Neutropenia: Obtain CBC prior to each dose. Administer granulocyte colony-stimulating factor (G-CSF) as secondary prophylaxis after an episode of febrile neutropenia or prolonged neutropenia. Dose modified per protocol.
• Diarrhea: Proactive management is essential. At the first sign of loose stools, initiate antidiarrheals (loperamide), increase fluid intake, and monitor electrolytes. For severe diarrhea (Grade ≥3), interrupt therapy, manage supportively, and resume at a reduced dose.
• Nausea/Vomiting: Use prophylactic antiemetic regimen.
• Infusion Reactions: Premedicate and monitor closely during infusion.

Serious Adverse Events

• Febrile Neutropenia / Serious Infection.
• Severe Dehydration and Electrolyte Imbalance from diarrhea.
• Hypersensitivity/Infusion Reactions.
• Embryo-Fetal Toxicity.

Research Areas:

Sacituzumab govitecan is a focus of extensive clinical research (2020-2025) aimed at expanding its use. Key areas include:

1. Moving to Earlier Lines of Therapy: Investigating its use as first- or second-line treatment in metastatic TNBC and HR+/HER2- breast cancer, both as monotherapy and in combination with other agents.
2. Combination Strategies: Actively studying combinations with immunotherapy (e.g., pembrolizumab), PARP inhibitors, and other targeted therapies to enhance efficacy.
3. Expansion into New Tumor Types: Clinical trials are underway in other Trop-2 positive cancers, including non-small cell lung cancer (NSCLC), gynecological cancers, and gastrointestinal malignancies.

Patient Management and Practical Recommendations:

Pre-treatment Tests:

• Complete Blood Count (CBC).
• Comprehensive Metabolic Panel, including liver and renal function.
• Pregnancy Test for women of childbearing potential.
• Trop-2 Testing (where available): While not required for approved uses, assessment can provide a biological rationale.

Precautions During Treatment:

• Premedication: Ensure premedication is administered 30-60 minutes prior to each infusion.
• Diarrhea Action Plan: Patients must have a clear plan for immediate loperamide use and know when to contact their healthcare team.
• Infusion Monitoring: Monitor for infusion reactions during and for at least 30 minutes after the first infusion.
• Fertility Warning: May impair fertility in males and females.

Do’s and Don’ts:

• DO start loperamide immediately at the first sign of loose stools and drink extra fluids.
• DO report fever (≥100.4°F), chills, signs of infection, or severe diarrhea (≥4 stools/day over baseline) immediately.
• DO attend all scheduled appointments for blood tests and infusions.
• DON’T take the anti-diarrheal medicine diphenoxylate/atropine for treatment-related diarrhea.
• DON’T become pregnant or father a child while on this medication and for specific periods after (consult your doctor).
• DON’T miss taking your premedication before your infusion.

Legal Disclaimer:

This guide is for informational purposes for patients and healthcare professionals. It summarizes the FDA-approved use and key risks of sacituzumab govitecan and is not a substitute for professional medical advice. Treatment decisions are highly individualized. Always consult your qualified healthcare provider for advice on your specific condition and treatment.